Effects of microglial cell changes on brain abnormalities in Alzheimer's patients with a specific genetic risk
Official title: Influence of microglial cell depletion and repopulation on aducanumab induced ARIA and vascular lesions in APOE4 carriers with AD
Funded at Roskamp Institute, INC. · NIH-11177901 · Data updated 2026-11-12
This study is looking at how changes in certain brain cells might affect side effects from a new treatment for Alzheimer's disease in people who have a specific gene called APOE4, to help find ways to make the treatment safer and more effective for them.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roskamp Institute, INC. NIH-funded |
| Lab location | 1 site (Sarasota, United States) |
| Project start | September 1, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $255,750 |
| NIH project number | 5R21AG089503-02 |
| Project ID | NIH-11177901 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with early Alzheimer's disease who are also carriers of the APOE4 allele.
✕Less likely to help
Patients who do not have Alzheimer's disease or do not carry the APOE4 allele may not benefit from this research.
What this research studies
This research investigates how the depletion and repopulation of microglial cells affect the occurrence of amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer's disease (AD) who carry the APOE4 allele. The study aims to understand the mechanisms behind ARIA, which are more frequent in APOE4 carriers, particularly in response to a new antibody therapy approved for early AD. By examining the relationship between microglial activation and cerebrovascular health, the research seeks to uncover potential pathways that could mitigate the adverse effects of treatment. Patients may undergo imaging and other assessments to evaluate the impact of these cellular changes on their condition.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that minimize the risks associated with new Alzheimer's therapies for APOE4 carriers.
How similar studies have gone: While there have been studies on microglial activation and its effects in Alzheimer's, this specific approach focusing on APOE4 carriers and ARIA is relatively novel.
Where this research is happening
-
Roskamp Institute, INC.
Sarasota, United States Active
Researchers
- Principal investigator: Ojo, Joseph O — Roskamp Institute, INC.
- Study coordinator: Ojo, Joseph O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.